Evidence map›Paper›PMID 40433397›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2025

Managing Small Airways Dysfunction in COPD Patients in Real Life Under Fixed Triple Combination of Beclomethasone/Formoterol/Glycopyrronium: The MASCOT Real World Evidence Study.

Athena Gogali, Konstantinos Kostikas, Christos Kyriakopoulos, Dimitrios Potonos, Konstantinos Porpodis, Ioanna Tsiouprou, Evangelia Fouka, Stavros Tryfon, Efthymia Papadopoulou, Maria Kipourou and 1 more

Registry-linked trialAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07372521 (Measuring Small-Airways Disease Improvement After Step-up to Extrafine TRIple or High-dose ICS/LABA in Patients Uncontrolled on Medium Dose ICS/LABA eXploring T2 Inflammation), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07372521 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Measuring Small-Airways Disease Improvement After Step-up to Extrafine TRIple or High-dose ICS/LABA in Patients Uncontrolled on Medium Dose ICS/LABA eXploring T2 Inflammation: The MATRIX Real-life Observational Study

Typeobservational_patient_registrySponsorUniversity Hospital, IoanninaRan2026 to 2028Enrolled130ConditionsAsthma
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Athena GogaliRespiratory Medicine Department, University of Ioannina, Ioannina, Greece.
Konstantinos KostikasRespiratory Medicine Department, University of Ioannina, Ioannina, Greece.ORCID 0000-0003-0774-3942
Christos KyriakopoulosRespiratory Medicine Department, University of Ioannina, Ioannina, Greece.ORCID 0000-0001-8806-2561
Dimitrios PotonosRespiratory Medicine Department, University of Ioannina, Ioannina, Greece.ORCID 0009-0006-6175-8036
Konstantinos PorpodisPulmonology Department, G. Papanikolaou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Ioanna TsiouprouPulmonology Department, G. Papanikolaou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Evangelia FoukaPulmonology Department, General Hospital of Thessaloniki "G. Papanikolaou", Thessaloniki, Greece.ORCID 0000-0003-4456-8987
Stavros TryfonPulmonology Department, General Hospital of Thessaloniki "G. Papanikolaou", Thessaloniki, Greece.
Efthymia PapadopoulouPulmonology Department, General Hospital of Thessaloniki "G. Papanikolaou", Thessaloniki, Greece.ORCID 0000-0002-2415-0842
Maria KipourouPulmonology Department, 424 Army General Hospital, Thessaloniki, Greece.
Konstantinos KatsoulisPulmonology Department, 424 Army General Hospital, Thessaloniki, Greece.

Funding

Chiesi Hellas SA
6 · The paper itself

Abstract

Introduction: The efficacy of the fixed extrafine combination of beclomethasone/formoterol/glycopyrronium (BDP/FF/G 87/5/9 μg) has been evaluated in randomized controlled trials of patients with chronic obstructive pulmonary disease (COPD). However, only few data exist on its effectiveness on small airways dysfunction (SAD). Methods: The MASCOT (MAnaging Small airways dysfunction in COPD patients in real life on the fixed Triple combination of BDP/FF/G 87/5/9 μg pMDI) prospective observational study evaluated the effectiveness of this combination on SAD in a period of 4 weeks, after direct switch from long-acting β Results: Between May 2022 and July 2023 we recruited 93 COPD patients (mean age 68.5 years, 82% men) with forced expiratory volume in 1 second (FEV Conclusion: Extrafine triple therapy improved SAD and spirometric parameters, leading to improvement in health status at 4 weeks. These results need to be confirmed in longer studies.

Indexed as

Adrenergic beta-2 Receptor AgonistsBeclomethasoneBronchodilator AgentsFormoterol FumarateGlucocorticoidsGlycopyrrolateLungMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveAdministration, InhalationAgedDrug CombinationsFemaleForced Expiratory VolumeHumansMaleAdrenergic beta-2 Receptor AgonistsBeclomethasoneBronchodilator AgentsDrug CombinationsFormoterol FumarateGlucocorticoidsGlycopyrrolateMuscarinic AntagonistsCOPDoscillometrysmall airwaystriple therapy

Identifiers

PMID40433397
PMCPMC12108956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.